Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia

Bone Marrow Transplantation volume 37, pages 745–749 (2006)Cite this article

Abstract

Multiply transfused patients of severe aplastic anemia are at increased risk of graft rejection. Five such patients underwent peripheral blood stem cell transplantation from HLA-identical siblings with a fludarabine-based protocol. The conditioning consisted of fludarabine 30 mg/m2/day × 6 days, cyclophosphamide 60 mg/kg/day × 2 days and horse antithymocyte globulin (ATG) × 4 days. Two different ATG preparations were used: ATGAM (dose 30 mg/kg/day × 4 days) or Thymogam (dose 40 mg/kg/day × 4 days). Engraftment: median time to absolute neutrophil count (ANC) >0.5 × 109/l was 11 days (range: 8–17) and median time to platelet count >20 × 109/l was 11 days (range: 9–17). At a median follow-up of 171 days (range: 47–389), there has been no graft rejection and all patients are in complete remission. Acute GVHD (grade 1) occurred in one patient only. Chronic GVHD developed in two patients (extensive in one and limited in another). The transplants were performed in non-HEPA filter rooms. In only one patient, systemic antifungal therapy (voriconazole) was used. The use of Thymogam brand of ATG for conditioning is being reported for the first time. Our experience suggests that this fludarabine-based protocol allows rapid sustained engraftment in high-risk patients without significant immediate toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Deeg HJ, Self S, Storb R, Doney K, Appelbaum FR, Witherspoon RP et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood 1986; 68: 1363–1368.

    CAS  PubMed  Google Scholar 

  2. Horowitz MM . Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000; 37: 30–42.

    Article  CAS  Google Scholar 

  3. Chandy M, Srivastava A, Dennison D, Mathews V, George B . Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 2001; 27: 785–790.

    Article  CAS  Google Scholar 

  4. Kang HJ, Shin HY, Choi HS, Ahn HS . Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 2004; 34: 939–943.

    Article  CAS  Google Scholar 

  5. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947–950.

    Article  CAS  Google Scholar 

  6. Johnsen HE, Baech J, Nikolajsen K . Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. Nordic Stem Cell Laboratory Group. J Hematother 1999; 8: 15–28.

    Article  CAS  Google Scholar 

  7. Storb R, Prentice RL, Thomas ED, Appelbaum FR, Deeg HJ, Doney K et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 1983; 55: 573–585.

    Article  CAS  Google Scholar 

  8. Storb R, Prentice RL, Thomas ED . Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977; 296: 61–66.

    Article  CAS  Google Scholar 

  9. Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269–275.

    CAS  Google Scholar 

  10. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490–2497.

    Article  CAS  Google Scholar 

  11. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606–613.

    CAS  Google Scholar 

  12. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–949.

    CAS  Google Scholar 

  13. Marsh JC, Ball SE, Darbyshire P, Gordon-Smith EC, Keidan AJ, Martin A et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003; 123: 782–801.

    Article  CAS  Google Scholar 

  14. Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005; 130: 747–751.

    Article  CAS  Google Scholar 

  15. Chan KW, Li CK, Worth LL, Chik KW, Jeha S, Shing MK et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant 2001; 27: 125–128.

    Article  CAS  Google Scholar 

  16. George B, Mathews V, Shaji RV, Srivastava V, Srivastava A, Chandy M . Fludarabine-based conditioning for allogeneic stem cell transplantation for multiply transfused patients with Fanconi's anemia. Bone Marrow Transplant 2005; 35: 341–343.

    Article  CAS  Google Scholar 

  17. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

  18. Korbling M, Anderlini P . Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98: 2900–2908.

    Article  CAS  Google Scholar 

  19. Bacigalupo A . Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225–231.

    Article  CAS  Google Scholar 

  20. Hayes-Lattin B, Leis JF, Maziarz RT . Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant 2005; 36: 373–381.

    Article  CAS  Google Scholar 

  21. Russell JA, Chaudhry A, Booth K, Brown C, Woodman RC, Valentine K et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000; 6: 109–114.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr A Srivastava and Dr M Chandy (Christian Medical College, Vellore, India) for sharing their experience in using different protocols for BMT in aplastic anemia.

Author information

Authors and Affiliations

  1. Department of Hematology, All India Institute of Medical Sciences, New Delhi, India

    R Kumar, S Prem, M Mahapatra, T Seth, D R Chowdhary, P Mishra, L Pillai, A M V R Narendra, R Saxena & V P Choudhry

  2. Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India

    N K Mehra

Authors
  1. R Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Prem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Mahapatra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Seth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D R Chowdhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Pillai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A M V R Narendra
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N K Mehra
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. V P Choudhry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, R., Prem, S., Mahapatra, M. et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant 37, 745–749 (2006). https://doi.org/10.1038/sj.bmt.1705321

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705321

Keywords

This article is cited by

Search

Advanced search

Quick links